182 related articles for article (PubMed ID: 36175678)
21. S100A9/CD163 expression profiles in classical monocytes as biomarkers to discriminate idiopathic pulmonary fibrosis from idiopathic nonspecific interstitial pneumonia.
Yamashita M; Utsumi Y; Nagashima H; Nitanai H; Yamauchi K
Sci Rep; 2021 Jun; 11(1):12135. PubMed ID: 34108546
[TBL] [Abstract][Full Text] [Related]
22. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.
Hara A; Sakamoto N; Ishimatsu Y; Kakugawa T; Nakashima S; Hara S; Adachi M; Fujita H; Mukae H; Kohno S
Respir Med; 2012 Apr; 106(4):571-80. PubMed ID: 22209187
[TBL] [Abstract][Full Text] [Related]
23. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.
Jo HE; Randhawa S; Corte TJ; Moodley Y
Drugs Aging; 2016 May; 33(5):321-34. PubMed ID: 27083934
[TBL] [Abstract][Full Text] [Related]
24. Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis.
Aoshima Y; Enomoto Y; Muto S; Meguro S; Kawasaki H; Kosugi I; Fujisawa T; Enomoto N; Inui N; Nakamura Y; Suda T; Iwashita T
Lung; 2021 Jun; 199(3):289-298. PubMed ID: 33770226
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis.
Kreuter M; Picker N; Schwarzkopf L; Baumann S; Cerani A; Postema R; Maywald U; Dittmar A; Langley J; Patel H
Respir Res; 2022 Mar; 23(1):62. PubMed ID: 35305632
[TBL] [Abstract][Full Text] [Related]
26. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue.
Caminati A; Lonati C; Cassandro R; Elia D; Pelosi G; Torre O; Zompatori M; Uslenghi E; Harari S
Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578211
[TBL] [Abstract][Full Text] [Related]
27. Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.
White ES; Xia M; Murray S; Dyal R; Flaherty CM; Flaherty KR; Moore BB; Cheng L; Doyle TJ; Villalba J; Dellaripa PF; Rosas IO; Kurtis JD; Martinez FJ
Am J Respir Crit Care Med; 2016 Nov; 194(10):1242-1251. PubMed ID: 27149370
[TBL] [Abstract][Full Text] [Related]
28. Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?
Collins BF; McClelland RL; Ho LA; Mikacenic CR; Hayes J; Spada C; Raghu G
Respir Med; 2018 Nov; 144S():S20-S27. PubMed ID: 30166087
[TBL] [Abstract][Full Text] [Related]
29. Comorbidities and risk of mortality among hospitalized patients with idiopathic pulmonary fibrosis in Spain from 2002 to 2014.
Pedraza-Serrano F; Jiménez-García R; López-de-Andrés A; Hernández-Barrera V; Esteban-Hernández J; Sánchez-Muñoz G; Puente-Maestu L; de-Miguel-Díez J
Respir Med; 2018 May; 138():137-143. PubMed ID: 29724386
[TBL] [Abstract][Full Text] [Related]
30. Validation of the recording of idiopathic pulmonary fibrosis in routinely collected electronic healthcare records in England.
Morgan A; Gupta RS; George PM; Quint JK
BMC Pulm Med; 2023 Jul; 23(1):256. PubMed ID: 37434192
[TBL] [Abstract][Full Text] [Related]
31. Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care.
Thickett D; Voorham J; Ryan R; Jones R; Coker R; Wilson AM; Yang S; Ow MY; Raju P; Chaudhry I; Hardjojo A; Carter V; Price DB
BMJ Open; 2020 May; 10(5):e034428. PubMed ID: 32474425
[TBL] [Abstract][Full Text] [Related]
32. Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.
Jovanovic DM; Šterclová M; Mogulkoc N; Lewandowska K; Müller V; Hájková M; Studnicka M; Tekavec-Trkanjec J; Littnerová S; Vašáková M;
Respir Res; 2022 May; 23(1):135. PubMed ID: 35624513
[TBL] [Abstract][Full Text] [Related]
33. Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea.
Lee HE; Myong JP; Kim HR; Rhee CK; Yoon HK; Koo JW
Int J Tuberc Lung Dis; 2016 Jul; 20(7):978-84. PubMed ID: 27287654
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
Xue M; Guo Z; Cai C; Sun B; Wang H
Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Cyclin D1 as a Discriminatory Immunohistochemical Biomarker for Idiopathic Pulmonary Fibrosis.
Wei CH; Baratelli FE; Xiao GQ; Koss MN; Elatre W
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):e11-e15. PubMed ID: 30095465
[TBL] [Abstract][Full Text] [Related]
36. Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis.
Naqvi SF; Lakhani DA; Sohail AH; Maurer J; Sofka S; Sarwari A; Hadi YB
BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34376400
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic update in idiopathic pulmonary fibrosis.
Chan AL; Rafii R; Louie S; Albertson TE
Clin Rev Allergy Immunol; 2013 Feb; 44(1):65-74. PubMed ID: 21222174
[TBL] [Abstract][Full Text] [Related]
38. Independent Clinical Factors Relevant to Prognosis of Patients with Idiopathic Pulmonary Fibrosis.
Song H; Sun D; Ban C; Liu Y; Zhu M; Ye Q; Yan W; Ren Y; Dai H
Med Sci Monit; 2019 Jun; 25():4193-4201. PubMed ID: 31166938
[TBL] [Abstract][Full Text] [Related]
39. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
Miyashita K; Kono M; Saito G; Koyanagi Y; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Nakamura Y; Suda T; Nakamura H
Clin Respir J; 2021 Mar; 15(3):336-344. PubMed ID: 33197284
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of Idiopathic Pulmonary Fibrosis Improve with Obesity: A Rural Appalachian Experience.
Sangani RG; Ghio AJ; Mujahid H; Patel Z; Catherman K; Wen S; Parker JE
South Med J; 2021 Jul; 114(7):424-431. PubMed ID: 34215896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
